Mazdutide

Metabolic & weight Investigational (in clinical trials)

GLP-1/glucagon dual receptor agonist · also known as IBI362, LY3305677

For reference only — not medical advice. Figures are commonly reported values compiled from published sources and may be wrong or out of date. Many compounds listed are not approved for human use. Talk to a licensed clinician before using any compound.

Mazdutide combines GLP-1 receptor activity, which reduces appetite and slows gastric emptying, with glucagon receptor activity, which is thought to add to energy expenditure and liver fat reduction. It was developed by Innovent Biologics with Eli Lilly and was approved in China in 2025 for chronic weight management, followed by an approval for type 2 diabetes. Elsewhere it remains investigational.

Commonly reported dosing (10 mg vial)

Reconstituted with 2 mL → 5 mg/mL.

Also sold in 5 mg vials.

Phase	Dose	Volume	U-100 units
Starting	2.5 mg	0.5 mL	50
Standard	5 mg	1 mL	100

Frequency: Once weekly, subcutaneous · Half-life: Long-acting; studied as a once-weekly injection

Open in calculator

Commonly reported dose escalation

Weeks	Dose	Volume	U-100 units
Weeks 1-4	2.5 mg	0.5 mL	50
Week 5+	5 mg	1 mL	100

Higher steps may need a larger vial or more than one draw. Escalation schedules vary; dosing decisions belong to a licensed clinician.

Commonly reported reconstitution steps

Vials are usually brought to room temperature (about 15-20 minutes) first.
2 mL of bacteriostatic water is added slowly down the inside wall of the 10 mg vial.
The vial is swirled gently until clear, not shaken.
This gives 5 mg/mL. Mixed vials are typically labeled with the date and refrigerated.

Storage

Before mixing: Lyophilized vials are commonly stored frozen (around -20 °C) and protected from light.

After mixing: Reconstituted solution is commonly kept refrigerated (2-8 °C), protected from light, and not frozen.

How it works

Dual agonism of the GLP-1 and glucagon receptors lowers food intake and body weight, and the glucagon component is thought to influence hepatic fat metabolism and energy use.

Researched for

Phase 3 GLORY-1 trial (4 mg and 6 mg weekly for 48 weeks) in adults in China with a high BMI.
Phase 2 and phase 3 programmes in type 2 diabetes and higher-dose studies (for example 9 mg) in Chinese adults.
A US-based phase 2 trial in adults with obesity or overweight.

Notes

Community charts step from 2.5 mg to 5 mg weekly, while the published phase 3 doses were 4 mg and 6 mg; the figures here are from the charts and differ from the trial arms.
Approved in China; not approved in the US.
Gastrointestinal events were the most frequently reported adverse events in trials, mostly mild to moderate.
At 2 mL a 10 mg vial gives 5 mg/mL, so 5 mg is 1 mL; at 3 mL it gives about 3.3 mg/mL.
A high-dose community chart continues to 7.5 and 10 mg weekly; 10 mg is an entire 10 mg vial and above the 4-6 mg phase 3 doses, so it is not tabulated.